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Abstract Hypoxia-inducible factor 1a (HIF1a) activates
the transcription of genes that are involved in angiogenesis
and cell survival. Over-expression of HIF1a caused by in-
tratumoral hypoxia and its genetic alterations are associated
with increased mortality in several cancer types including
non-small-cell lung cancer (NSCLC). The aim of this study
was to investigate the predictive role of single nucleotide
polymorphisms (SNPs) in HIF1A gene in NSCLC out-
comes. We genotyped two functional SNPs (rs2057482 and
rs2301113) in HIF1A gene and assessed their associations
with clinicopathological parameters and prognosis of 494
NSCLC patients by Cox proportional hazard model. There
was no significant association between the SNPs and clin-
ical outcomes of NSCLC for overall analysis. However, in
stratified analysis for NSCLC patients at early stage (I/II),
we observed a protective effect conferred by variant geno-
type of rs2057482 on overall survival (OS) (HR 0.42, 95 %
CI 0.22–0.80) and recurrence-free survival (RFS) (HR 0.60,
95 % CI 0.36–0.97) in a dominant model. Additionally,
multivariate Cox analysis based on dominant model indi-
cated that significant increased death and recurrence risks
were observed in patients with early T-stage (T1 and T2)
tumors, who carrying variant-containing genotype of
rs2301113, as well as in patients without lymph node
involvement (N0 stage) for rs2057482. Genetic variations
on HIF1A gene are significantly associated with NSCLC
outcomes in patients with early stage disease.
Keywords HIF1A  Single nucleotide polymorphism 
Association study  Non-small-cell lung cancer
Introduction
Lung cancer is the leading cause of cancer-related death
worldwide. Non-small-cell lung cancer (NSCLC) repre-
sents 75–85 % of all lung cancer cases. The median sur-
vival time of patients with untreated metastatic NSCLC is
only 4–5 months, with a 1-year survival rate of only 10 %
[1, 2]. Up to date, the prediction of NSCLC prognosis
largely depends on the conventional prognostic factors
such as disease stage and performance status. NSCLC
patients with the same pathological features, however, have
dramatically distinct response to chemotherapies and have
different survival outcomes, suggesting the importance of
novel biomarkers for the prognosis of NSCLC [3].
Hypoxia-inducible factor-1 (HIF1) is a key regulator of
cellular response to hypoxia and plays essential roles in
regulating angiogenesis, cell adhesion, energy metabolism,
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and apoptosis [4–8]. HIF1 is a heterodimeric transcriptional
complex consisting of a and b subunits, in which HIF1a is
the oxygen-regulated factor that determines the activity of
HIF1 [9]. Since hypoxia-induced angiogenesis is required
for tumor growth, HIF1a is heavily involved in the devel-
opment and progression of several types of human malig-
nancies [10–13]. For example, overexpression of HIF1a
increased the invasive capacity of human lung adenocarci-
noma cells [14], while antisense oligonucleotide of HIF1a
inhibited the proliferation of lung cancer cells both in vitro
and in vivo [15]. Besides, the expression of HIF1a is asso-
ciated with the prognosis of cancer patients. For example,
lung squamous cell carcinoma patients with high HIF1a
expression in tumor cells and low expression in stromal cells
had better survival [16]. In lung adenocarcinoma, expression
of HIF1a was significantly higher in cases with vascular
invasion, lymph node involvement, and vascular endothelial
growth factor-A expression [17]. Similarly, the expression
level of HIF1a was significantly higher in tumor tissue than
in the corresponding non-tumor lung tissue and was associ-
ated with a shorter survival time in NSCLC [16, 18–20]. In
contrast, patients with HIF-positive carcinomas had signifi-
cantly longer median survival time than patients with HIF-
negative carcinomas [21]. All these data strongly support the
hypothesis that the presence of HIF1 may serve as a prog-
nostic biomarker for the survival of NSCLC patients.
The HIF1A gene is highly polymorphic, and its
expression and activity are dramatically affected by various
polymorphisms. In addition to its expression, polymor-
phisms of HIF1A have also been implicated in the carci-
nogenesis of several malignancies. For example, two single
nucleotide polymorphisms (SNPs) rs11549465 and
rs11549467 on HIF1A locus, which resulted in proline-to-
serine and alanine-to-threonine amino acid substitutions,
respectively, were found to be associated with unfavorable
prognosis in oral squamous cell carcinoma [22]. When it
came to cancer risks, there was a significant association
between rs11549465 and the risk of developing colorectal
cancer [23], and the combined variant genotypes of
rs2057482 and rs11549467 were associated with increased
prostate cancer risk [24]. In addition, rs11549467 has been
involved in the progression of pancreatic ductal adeno-
carcinoma [25]. Given the important role of HIF1a in the
progression of NSCLC, it is plausible that polymorphisms
of HIF1A may affect the biological behavior and prognosis
of NSCLC. Up to date, however, there is no report on the
role of HIF1A polymorphism in NSCLC prognosis. In this
study, we for the first time investigated the association
between HIF1A polymorphisms and prognosis of NSCLC
in our ongoing hospital-based cohort study in a Chinese
Han population. We assessed the effects of 2 functional
SNPs in HIF1A on recurrence and survival in 494 NSCLC
patients undergoing surgical treatment.
Materials and methods
Study population
A total of 564 patients with incident NSCLC were initially
recruited into an ongoing molecular epidemiological study
at the Department of Thoracic Surgery of Tangdu Hospital,
the Fourth Military Medical University, Xi’an, China from
July 2009 to December 2011. There was no restriction for
case recruitment. All patients were newly diagnosed and
histologically confirmed with NSCLC. In the present study,
we excluded 70 patients, including 17 patients who did not
undergo surgery or only received palliative operation, 38
patients who had incomplete clinical information, 6
patients who were not Han Chinese, 6 patients died within
2 months after surgery, 3 patients had relapsed within
1 month, and finally, 494 patients were included in this
study. This study was approved by the Ethic Committee of
the Fourth Military Medical University, and all experi-
mental procedures were performed according to Helsinki
Declaration. Signed informed consent was obtained from
each participant.
Demographic and clinical data
Demographic data were collected through in-person inter-
views using a standardized epidemiological questionnaire,
including age, gender, ethnicity, residential region, smok-
ing status, alcohol use, education status, and family history
of cancer. Detailed clinical information was collected
through medical chart review or consultation with treating
physicians, including time of diagnosis, time of surgery
and/or chemotherapies, time of recurrence and/or death,
tumor stage, differentiation, location site, lymph node
invasiveness, and treatment protocol. The tumor histolog-
ical grade was assessed according to WHO criteria, and
tumors were staged using the 7th edition TNM staging
system based on post-operative pathological examination
of the specimens after surgery. A standard follow-up was
performed by a trained clinical specialist through on-site
interview, direct calling, or medical chart review. The
latest follow-up data in this analysis were obtained in
August 2012, and 37 (6.56 %) patients were lost during
follow-up. For each patient enrolled, 5 ml of venous blood
was available for genomic DNA extraction using the
E.Z.N.A. Blood DNA Midi Kit (Omega Bio-Tek, Norcross,
GA) in the laboratory.
SNP selection and genotyping
Functional SNPs in HIF1A gene were selected using a set
of Web-based SNP selection tools (freely available at
http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm), by which
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one can select SNPs based on linkage disequilibrium and
predict functional characteristics of both coding and non-
coding SNPs. The 50- and 30-flanking regions were arbi-
trarily set at 1,000 bp for all genes. Only validated SNPs
were selected, and SNPs with minor allele frequency\5 %
in the Asian population were excluded. In the case of mul-
tiple potentially functional SNPs within the same haplotype
block (defined by the linkage coefficient r2 [ 0.8), none of
SNPs was included. Functional SNPs include non-synony-
mous SNPs in exons, SNPs in miRNA binding sites of
30-untranslated region (UTR), SNPs in the transcription
factor binding site of the 50 flanking region, and SNPs in
splice sites. Finally, we found only one functional SNP locus
(rs2057482), which located in the 30-UTR. Another SNP
locus, rs2301113, was selected as previous studies reported
[26, 27]. Genotyping was performed using Sequenom
iPLEX genotyping system (Sequenom Inc, CA). Laboratory
personnel conducting genotyping was blinded to patient
information. The average call rate for the SNP array was
99.5 %. Strict quality control measures were implemented
during genotyping with[99.0 % concordance with the main
genotyping results.
Statistical analysis
SPSS19.0 statistics software was used for all statistical
analyses. Two major endpoints were analyzed in this
study, which were overall survival (OS) and recurrence-
free survival (RFS). OS time was defined as the date from
primary NSCLC diagnosed to the date of death from any
causes. RFS time was defined as the date from cancer
diagnosis to the date of the first time disease recurrence.
Patients who were still alive at the last contact date were
censored for the OS analysis, and those who did not
develop recurrence at the last contact date were censored
for the RFS analysis. The three genetic models (additive,
dominant, and recessive) were applied to assess the
association of single SNPs with clinical outcomes of
NSCLC patients. Considering that there was a very small
number (B5) of patients with the rare homozygous variant
genotype for 2 SNPs of HIF1A gene, we did not analyze
the recessive model for these 2 SNPs. Hazards ratios
(HRs) and 95 % confidence intervals (CIs) were estimated
by a multivariate Cox proportion hazards model, adjusting
for age, gender, smoking status, histology, TNM stage,
differentiation, and adjuvant therapy. A powerful boot-
strap resampling was performed 100 times to reduce the
potential spurious findings. Kaplan–Meier curve and log-
rank test were used to assess the differences of patient
groups with different genotypes for OS and RFS. All
P values in this study were two-sided. P \ 0.05 was
considered as statistical significant.
Results
Distribution of patients characteristics and prognosis
analysis
Characteristics of 494 NSCLC patients were summarized
in Table 1. Among these 494 patients, the median age at
the time of diagnosis was 59 years (ranging from 27 to
86 years), and 385 (77.9 %) were males. There were 270
patients diagnosed with squamous cell carcinoma, 149 with
adenocarcinoma, and 75 with other types of NSCLC,
including 55 with adenosquamous carcinoma, 15 with
carcinosarcoma, 3 with large-cell lung cancer, and 2 with
mucoepidermoid carcinoma. The pathological stages were
as follows: 287 at stage I/II (58.1 %) and 207 at stage III
(41.9 %). The majority of patients (69.8 %) had well or
moderately differentiated tumors, and 365 (73.9 %)
patients had received adjuvant chemotherapy or radio-
therapy after surgery. In the follow-up period of
20.3 months, 149 (30.2 %) patients died and 209 (42.3 %)
patients developed recurrence.
Multivariate Cox regression analyses were performed to
assess the prognostic effects of clinical characteristics such
as age, gender, smoking status, histology, TNM stage, dif-
ferentiation grade, and adjuvant therapy (Table 1). Our
analyses showed that patients with advanced TNM stage
(stage III) had significant higher death risk (HR 1.85, 95 %
CI 1.33–2.57) and recurrence risk (HR 1.94, 95 % CI
1.47–2.56), comparing to those with early TNM stages
(I ? II) for OS and RFS, respectively. As expected, patients
who received adjuvant chemotherapy or radiotherapy
exhibited significantly reduced death risk (HR 0.44, 95 % CI
0.31–0.63) and recurrence risk (HR 0.72, 95 % CI
0.57–0.99), comparing to those without adjuvant therapy for
OS and RFS, respectively. Additionally, significantly
increased recurrence risks were also observed in patients
with lymph nodes involvement (P = 0.032) or poorly and
undifferentiated tumors (P = 0.013).
Association of HIF1A SNPs with clinical outcomes
in NSCLC patients
We assessed the effect of 2 SNPs (rs2057482 and
rs2301113) in HIF1A gene on death and recurrence in
NSCLC patients using a multivariate Cox regression
model. However, there was no significant association
observed between the two polymorphisms and OS or RFS
in the analysis (Online resource Table 1). We then per-
formed a stratified analysis to evaluate OS and RFS in
different strata of patients’ characteristics in NSCLC
patients. Surprisingly, as shown in online resource Table 2
and Table 2, significant protective effects of variant-con-
taining genotypes of rs2057482 were observed in patients
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with early stage (TNM stage I ? II) for both OS (HR 0.42,
95 % CI 0.22–0.80) and RFS (HR 0.60, 95 % CI
0.36–0.97) analyses, when comparing to those carrying
wild-type genotype. To internally validate the results, we
next performed random bootstrap sampling of the signifi-
cant SNP (rs2057482) for 100 iterations and listed the
number of times that the P value was\0.05. In early stage
(I ? II) patients, highly consistent results were observed,
with bootstrap P \ 0.05 for 100 of the sampling in OS and
62 of the sampling in RFS. We also observed significant
associations between variant-containing genotypes of both
SNPs and reduced recurrence risk in patients with well and
moderate differentiated tumors, when comparing to those
carrying wild-type genotype. The Kaplan–Meier curve
analyses consistently showed that in early stage (I ? II),
NSCLC patients who carrying variant-containing geno-
types of rs2057482 had significant longer overall survival
time (log rank P = 0.005) (Fig. 1) and time to recurrence
(log rank P = 0.047) (Online resource Fig 1), when
comparing to those carrying wild-type genotype. Since
tumor stage is the most effective prognostic factor in
predicting cancer patients’ survival, we further focused
the analyses of SNPs and NSCLC patients’ outcomes by
different stage diseases.
Table 1 Distribution of patients’ characteristics and prognosis analysis
Variable No. of total
patients (%)











B59 244 (49.4) 71 (47.7) Ref. 110 (52.6) Ref.
[59 250 (50.6) 78 (52.3) 0.89 (0.63–1.25) 0.503 99 (47.4) 0.84 (0.63–1.11) 0.217
Gender
Female 109 (22.1) 32 (21.5) Ref. 50 (23.9) Ref.
Male 385 (77.9) 117 (78.5) 1.07 (0.61–1.87) 0.826 159 (76.1) 1.16 (0.72–1.87) 0.532
Smoking status
Never smoker 154 (31.2) 45 (30.2) Ref. 70 (33.5) Ref.
Ever smoker 340 (68.8) 104 (69.8) 0.94 (0.57–1.56) 0.812 139 (66.5) 0.77 (0.50–1.17) 0.224
Histology
Squamous cell carcinoma 270 (54.7) 79 (53.0) Ref. 109 (52.2) Ref.
Adenocarcinoma 149 (30.2) 33 (22.1) 0.59 (0.38–0.92) 0.020 57 (26.8) 0.74 (0.52–1.06) 0.108
Othersb 75 (15.1) 37 (24.8) 1.54 (0.91–2.59) 0.106 44 (21.1) 1.22 (0.78–1.93) 0.375
TNM Stage
I/II 287 (58.1) 74 (48.7) Ref. 98 (46.9) Ref.
III 207 (41.9) 78 (51.3) 1.85 (1.33–2.57) \0.001 111 (53.1) 1.94 (1.47–2.56) \0.001
T-stage
T1/2 306 (61.9) 80 (53.7) Ref. 117 (56.0) Ref.
T3/4 188 (38.1) 69 (46.3) 1.41 (0.98–2.05) 0.067 92 (44.0) 1.24 (0.90–1.70) 0.184
N-stage
N0 231 (46.8) 60 (40.3) Ref. 77 (36.8) Ref.
N1/2/3 263 (53.2) 89 (59.7) 1.45 (0.87–2.44) 0.161 132 (63.2) 1.60 (1.05–2.46) 0.032
Differentiation
Well/moderate 345 (69.8) 85 (57.0) Ref. 125 (59.8) Ref.
Poorly/undifferentiated 149 (30.2) 64 (43.0) 1.35 (0.89–2.07) 0.163 84 (40.2) 1.56 (1.10–2.22) 0.013
Adjuvant therapy
No 129 (26.1) 45 (30.2) Ref. 52 (24.9) Ref.
Yes 365 (73.9) 104 (69.8) 0.44 (0.31–0.63) \0.001 157 (75.1) 0.72 (0.53–0.99) 0.040
CI confidence interval, HR hazard ratio, Ref reference
a HRs were adjusted for age, gender, smoking status, histology, TNM stage, differentiation and adjuvant chemotherapy or radiotherapy, where
appropriate
b Other carcinomas include adenosquamous carcinoma, large cell carcinoma, carcinosarcoma, and mucoepidermoid carcinoma
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Association of HIF1A SNPs with clinical outcomes
in different T-stage or N-stage disease
We further analyzed the associations between the SNPs
and more detailed tumor stages of T-stage (tissue invasion)
or N-stage (lymph nodes involvement), and stratified the
analyses by stage status. As the data shown in Table 3, the
OS analysis results of significant associations between
reduced death risks and variant-containing genotypes of
SNP rs2057482 (HR 0.60, 95 % CI 0.36–1.00, P = 0.050)
and rs2301113 (HR 0.60, 95 % CI 0.38–0.93, P = 0.023)
were consistently observed in patients with early T-stage
(I ? II), instead of in patients with advanced T-stages,
when comparing to those carrying wild-type genotype.
Similarly, for RFS analysis, we also observed the signifi-
cant associations between variant-containing genotypes of
rs2057482 or rs2301113 and reduced recurrence risk with
HR of 0.59 (95 % CI 0.39–0.90, P = 0.015) and 0.61
(95 % CI 0.42–0.89, P = 0.010), respectively, in patients
with early T-stage diseases (Table 3). Moreover, the vari-
ant-containing genotypes of rs2053482 exhibited signifi-
cant associations with reduced death risk (HR 0.34, 95 %
CI 0.16–0.73, P = 0.005) and recurrence risk (HR 0.49,
95 % CI 0.27–0.86, P = 0.014) in patients without lymph
node involvement (N0 stage patients), comparing to those
carrying wild-type genotype (Table 3). Attenuated similar
results were also observed in the same analyses for SNP
rs2301113 with borderline significance in OS (P = 0.063)
and RFS (P = 0.084) analyses, in patients without lymph
node involvement (Table 3). The Kaplan–Meier curve
analyses indicated that variant-containing genotypes of
rs2301113 significantly distinguished patients with better
survival in OS and RFS analyses from those carrying wild-
type genotype with log rank P value of 0.033 and 0.015,
respectively, in patient group with early T-stage, instead of
in patient group with advanced T-stage disease (Fig. 2 for
OS and Online resource Fig. 2 for RFS). While for SNP
rs2057482, the variant-containing genotypes significantly
distinguished patients with better survival in patients
without lymph node involvement in OS and RFS analyses
with log rank P value of 0.002 and 0.010, respectively
(Fig. 3 for OS and Online resource Fig 3 for RFS).
Discussion
In the present study, we evaluated the effects of 2 func-
tional SNPs in HIF1A on the prognosis of NSCLC patients.
Although there was no statistical significant association to
be found in the primary analyses, significant associations
were observed in the stratified analysis between variant-
containing genotypes of SNPs and reduced death or recur-
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diseases, in patients with early T-stage, and in patients
without lymph node involvement (early N-stage). Our data
indicated that functional SNPs in HIF1A gene had a
potential predictive role in prognosis of early stage
NSCLC.
Previous study demonstrated that overexpression of
HIF1a accelerated glycolysis in A549 NSCLC cells [28].
Elevated level of HIF1a was associated with increased
tumor-xenograft growth, whereas inhibition of HIF1
activity remarkably impaired tumor growth in vivo [29,
30]. The specific consequences of increased HIF1 activity,
however, varied according to different cell types. In clini-
cal studies focusing on the association between HIF1a
expression and prognosis of cancers, the conclusions were
contradictory. Volm and Koomagi showed that patients
with HIF1a-positive carcinomas had significantly longer
median survival time than patients with HIF1a-negative
carcinomas [21]. Moreover, Kuo and colleagues investi-
gated the role of 2 non-synonymous SNPs (rs11549465 or
Pro582Ser and rs11549467 or Ala588Thr) in coding region
of HIF1A gene in NSCLC and found that patients carrying
T/T genotype of rs11549465 or A/A genotype of
rs11549467 had increased cancer risk compared with
patients carrying other genotypes [31]. However, the
association between the polymorphisms in HIF1A gene and
NSCLC cancer prognosis is not well investigated so far.
Our study indicate that rs2057482 was associated with both
OS and RFS in patients with early stage (I ? II) NSCLC.
Furthermore, we evaluate the effect of rs2057482 and
rs2301113 in patients with different T- and N-stages sep-
arately. The significant or borderline significant protect
effects of variant-containing genotypes of rs2301113 and
rs2057482 on OS and RFS were observed only in patients
with early T-stage or N-stage diseases, but not in patients
with advanced T-stage or N-stage disease. Our findings
provide epidemiological evidence that polymorphism in
HIF1A gene may serve as prognostic factor in NSCLC,
especially in early stage disease, although the underlying
mechanism needs further investigation.
HIF1 is a transcription factor that controls the expression
of more than 40 target genes which encode proteins that
play crucial roles in tumor progression, such as vascular
endothelial growth factor (VEGF), glucose transporters 1
and 3 (GLUT1, GLUT3), and glycolytic enzymes [32]. In
Fig. 1 Kaplan–Meier curves of
overall survival by dominant
model in patient subgroups with
different disease stages. a The
analysis of rs2057482 in
patients with early stage
disease; b rs2057482 in patients
with advanced stage disease;
c rs2301113 in patients with
early stage disease; d rs2301113
in patients with advanced stage
disease
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Table 3 Associations between SNPs and NSCLC outcomes in subgroups of patients with different T-stage or N-stage disease
SNP Variables Genotypes Overall survival Recurrence-free survival
Death/total HR (95 % CI)a P value Recurrence/total HR (95 % CI)a P value
rs2057482 T1?T2 CC 59/202 Ref. 85/202 Ref.
CT?TT 21/103 0.60 (0.36–1.00) 0.050 31/103 0.59 (0.39–0.90) 0.015
T3?T4 CC 51/142 Ref. 69/142 Ref.
CT?TT 17/44 1.39 (0.78–2.46) 0.263 22/44 1.15 (0.70–1.91) 0.576
N0 CC 52/159 Ref. 62/159 Ref.
CT?TT 8/72 0.34 (0.16–0.73) 0.005 15/72 0.49 (0.27–0.86) 0.014
N1?N2?N3 CC 58/185 Ref. 92/185 Ref.
CT?TT 30/75 1.34 (0.85–2.11) 0.209 38/75 1.02 (0.69–1.51) 0.921
rs2301113 T1?T2 AA 43/132 Ref. 61/132 Ref.
AC?CC 37/173 0.60 (0.38–0.93) 0.023 55/173 0.61 (0.42–0.89) 0.010
T3?T4 AA 29/87 Ref. 40/87 Ref.
AC?CC 39/100 1.37 (0.84–2.26) 0.210 51/100 1.34 (0.88–2.04) 0.176
N0 AA 35/110 Ref. 43/110 Ref.
AC?CC 25/121 0.61 (0.36–1.03) 0.063 34/121 0.67 (0.42–1.06) 0.084
N1?N2?N3 AA 37/109 Ref. 58/109 Ref.
AC?CC 51/152 1.02 (0.67–1.57) 0.922 72/152 0.93 (0.66–1.33) 0.697
a HRs were adjusted for age, gender, smoking status, histology, differentiation and adjuvant chemotherapy or radiotherapy
Fig. 2 Kaplan–Meier curves of
overall survival by dominant
model in patient subgroups with
different T-stages. a The
analysis of rs2057482 in
patients with early T-stage
disease; b rs2057482 in patients
with advanced T-stage disease;
c rs2301113 in patients with
early T-stage disease;
d rs2301113 in patients with
advanced T-stage disease
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breast cancer, HIF1a overexpression can be detected in
ductal carcinoma in situ, the pre-invasive stage at which
angiogenesis is first induced [33]. HIF1a was also overex-
pressed in preneoplastic and premalignant lesions such as
colonic adenoma and prostate intraepithelial neoplasia.
HIF1a-positive cells were prominent at tumor margins and
surrounding areas of neovascularization [34], implying that
up-regulation of HIF1a was an early molecular event in
carcinogenesis and tumor invasiveness. These features of
HIF1a may explain the predictive role of polymorphisms in
HIF1A gene in early stage of NSCLC. Hypothetically, in
advanced NSCLC, the variation in HIF1A has some effect
on survival, but could not as the independent prognostic
factor due to other molecular factors and microenviron-
mental elements involved in tumor growth. Evidence on
this concept is further warranted, and more future research
work is needed to elucidate whether our findings can be
explained by stage specificity role of HIF1A SNPs in tumor
progression.
SNP rs2057482 which was significantly associated
with NSCLC prognosis is located in the 30-UTR of the
HIF1A gene. Previous studies have shown that the
polymorphisms in the 30-UTRs of several genes were
associated with miRNA-regulated protein expression by
providing mutated binding sites for proteins and mi-
croRNAs to alter mRNA stability, or by forming hairpin
loop structures to stabilize mRNA and thus slow down
degradation [35]. It is assumed that SNP rs2057482 at 30-
UTR might alter HIF1A gene expression and subse-
quently affect survival of NSCLC patients. Further study
is needed to verify our assumption.
In summary, as the first study observing the effects of
HIF1A polymorphisms on NSCLC prognosis, our results
strongly suggest that SNPs of HIF1A (rs2057482 and
rs2301113) are independent prognostic markers for early
stage NSCLC patients after surgery. Large-scale studies
will be carried out in the future to further validate the
findings of the present study.
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Fig. 3 Kaplan–Meier curves of
overall survival by dominant
model in patient subgroups with
different N-stages. a The
analysis of rs2057482 in
patients without lymph node
involvement; b rs2057482 in
patients with positive lymph
nodes involvement; c rs2301113
in patients without lymph node
involvement; d rs2301113 in
patients with positive lymph
nodes involvement
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